AptarGroup Inc (ATR)vsAstraZeneca PLC (AZN)
ATR
AptarGroup Inc
$113.36
+0.72%
HEALTHCARE · Cap: $7.51B
AZN
AstraZeneca PLC
$183.02
+1.10%
HEALTHCARE · Cap: $284.30B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1461% more annual revenue ($60.44B vs $3.87B). AZN leads profitability with a 17.2% profit margin vs 10.0%. AZN appears more attractively valued with a PEG of 1.38. AZN earns a higher WallStSmart Score of 64/100 (C+).
ATR
Buy53
out of 100
Grade: C-
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-44.1%
Fair Value
$97.16
Current Price
$113.36
$16.20 premium
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$183.02
$11.55 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Earnings declined 4.3%
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ATR
The strongest argument for ATR centers on Price/Book. Revenue growth of 10.8% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ATR
The primary concerns for ATR are PEG Ratio, Piotroski F-Score, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ATR profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ATR carries more volatility with a beta of 0.40 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 53/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AptarGroup Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
AptarGroup, Inc. offers a range of packaging, dispensing and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectables, and food and beverage markets. The company is headquartered in Crystal Lake, Illinois.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?